Demecarium

Summary

Demecarium (CHEMBL1201229) is an approved small molecule (ATC S01EB04); indicated across 1 condition including glaucoma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: S01EB04
• Indications: 1 condition
• Chemistry: 556.8 Da · C32H52N4O4+2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201229
Name	Demecarium
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5966
ChEBI	CHEBI:59719
ATC	S01EB04
Molecular formula	C32H52N4O4+2
Molecular weight	556.8
InChIKey	RWZVPVOZTJJMNU-UHFFFAOYSA-N

SMILES: CN(CCCCCCCCCCN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C)C(=O)OC2=CC=CC(=C2)[N+](C)(C)C

IUPAC name: trimethyl-[3-[methyl-[10-[methyl-[3-(trimethylazaniumyl)phenoxy]carbonylamino]decyl]carbamoyl]oxyphenyl]azanium

ChEBI definition: The bis(quaternary ammonium) dication obtained by N,N’-dimethylation of the N,N’-bis[3-(dimethylamino)phenyl carbamate] derivative of 2,13-diazatetradecane.

Also known as: Demecarium, Demecarium cation, Demecarium ion, DEMECARIUM, demecarium

Parent form; salt/anhydrous children: CHEMBL1200514

Patent coverage: 741 distinct patent families (2,555 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 2,554 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
glaucoma	4	MONDO:0005041	MONDO:0005041

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).